New Launch22 Dec 2025, 11:42 am
Emcure Pharmaceuticals Launches Weight Management Therapy Poviztra® at 8790/- per month
AI Summary
Emcure Pharmaceuticals Ltd. has announced the commercial launch of Poviztra®, a second brand of Novo Nordisk’s Semaglutide injection for weight management, priced at 8790/- per month. The once-weekly pen device comes in five strengths and is supported by extensive clinical evidence. It is indicated for chronic weight management in adults with obesity or overweight and at least one weight-related comorbid condition. The launch marks an important step in expanding equitable access to scientifically validated weight-management solutions.
Key Highlights
- Emcure Pharmaceuticals launches Poviztra®, a second brand of Novo Nordisk’s Semaglutide injection for weight management.
- Poviztra® is priced at 8790/- per month and is available in a once-weekly pen device in five strengths.
- The product is supported by extensive clinical evidence from the STEP and SELECT clinical trial programmes.
- Poviztra® is indicated for chronic weight management in adults with obesity or overweight and at least one weight-related comorbid condition.
- The launch marks an important step in expanding equitable access to scientifically validated weight-management solutions.